Lynx1 Capital Management LP
Source: SEC Form 13F · as of Mar 2026Lynx1 Capital Management LP holds 21 biotech & pharma companies tracked by BioSniper, totaling $632.6M in value as of Mar 2026 (SEC Form 13F).
Companies held
21
Total value held
$632.6M
BioSniper AIPage evidence connected
Prepared research question
What matters most for Stoke Therapeutics, Inc. (STOK)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| STOKStoke Therapeutics, Inc. | 4,763,673 | $155.1M |
| GHRSGH Research PLC | 10,763,288 | $151.3M |
| CGEMCullinan Therapeutics, Inc. | 8,963,500 | $127.4M |
| AGIOAGIOS PHARMACEUTICALS, INC. | 2,611,568 | $88.3M |
| DNLIDenali Therapeutics Inc. | 1,880,303 | $36.1M |
| CCCCC4 Therapeutics, Inc. | 6,998,902 | $18.4M |
| KRROKorro Bio, Inc. | 1,538,296 | $17.4M |
| TCRXTScan Therapeutics, Inc. | 8,019,148 | $8.1M |
| XNCRXencor Inc | 536,398 | $6.5M |
| DTILPRECISION BIOSCIENCES INC | 985,113 | $5.4M |
| PASGPassage BIO, Inc. | 623,704 | $4.9M |
| NEUPNeuphoria Therapeutics Inc. | 875,328 | $3.6M |
| TRDAEntrada Therapeutics, Inc. | 211,689 | $2.7M |
| CGONCG Oncology, Inc. | 31,591 | $2.1M |
| IMTXImmatics N.V. | 216,973 | $2.1M |
| DSGNDesign Therapeutics, Inc. | 119,516 | $1.3M |
| YARWVYNE Therapeutics Inc. | 1,628,700 | $973K |
| HOWLWerewolf Therapeutics, Inc. | 657,786 | $548K |
| IBIOiBio, Inc. | 68,076 | $129K |
| PRQRProQR Therapeutics N.V. | 68,486 | $111K |
| ABSIAbsci Corporation | 21,245 | $64K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.